Results 141 to 150 of about 2,404 (154)

Correction: Factors Associated With Newborn Nirsevimab Administration in Los Angeles County During the 2024 Respiratory Syncytial Virus Season. [PDF]

J Pediatric Infect Dis Soc
europepmc   +1 more source

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein. [PDF]

Vaccines (Basel)
Paes BA, Manzoni P, Fullarton JR, Rodgers-Gray BS, Carbonell-Estrany X.   +4 more
europepmc   +1 more source

Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status. [PDF]

Vaccines (Basel)
Ladomenou F, Psarra IA, Gkentzi D.
europepmc   +1 more source

Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study

Lancet Regional Health - Europe, The
International audienceRespiratory syncytial virus (RSV) is the leading cause of lower-respiratory-tract infection in children. Nirsevimab, a monoclonal antibody against RSV, was implemented in a few countries in September 2023.
Andreas Werner, Corinne Levy, Stéphane Bechet   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France

EClinicalMedicine
Francois Dubos
exaly  

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Journal of Infection
Ushma Wadia, Catherine Pienaar, Lana Bell   +2 more
exaly  

Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024

Influenza and Other Respiratory Viruses
Sophie Vaux, Cecile Durand, Milési Christophe   +2 more
exaly  

Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis

The Lancet Regional Health Americas
Stephanie A. Irving, Elizabeth Rowley, Brian E. Dixon   +2 more
exaly  

Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

Vaccine
April Killikelly, Man Wah Yeung
exaly  

Effectiveness of nirsevimab against hospitalisation for RSV-bronchiolitis during high RSV-B circulation in the second year of nationwide implementation in France: a test-negative case-control study

Lancet Regional Health - Europe, The
Romain Anne-Sophie, Robert Cohen, Valérie Biran   +2 more
exaly